FrancophonIA/ELRC3.0 huggingface dataset:
English: Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.
Estonian: Müügipakendis veterinaarpreparaadi kõlblikkusaeg: 3 aastat.
English: In the absence of compatibility studies, this veterinary medicinal product must not be mixed with
Estonian: Sobivusuuringute puudumisel ei tohi seda veterinaarravimit segada teiste veterinaarravimitega.
English: Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Estonian: Ligikaudu 75% manustatud annusest väljutatakse roojaga ja ülejäänud osa uriiniga.
English: Flexicam 5 mg/ml solution for injection for dogs and cats
Estonian: Flexicam 5 mg/ml süstelahus koertele ja kassidele
English: 1 ml of solution for injection contains 5 mg of meloxicam.
Estonian: 1 ml süstelahust sisaldab 5 mg meloksikaami.
English: Flexicam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Estonian: Flexicami ei tohi manustada koos teiste mittesteroidsete põletikuvastaste ravimite ega glükokortikosteroididega.
English: In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Estonian: In vitro ja in vivo uuringutes inhibeeris meloksikaam tsüklooksügenaasi-2 (COX-2) rohkem kui tsüklooksügenaasi-1
English: Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 µg/ml in dogs and 1.1 µg/ml in cats were reached approximately 2.5 hours and 1.5 hours post administration, respectively.
Estonian: Subkutaansel manustamisel on meloksikaam täielikult biosaadav ja maksimaalne keskmine kontsentratsioon plasmas 0,73 g/ml koertel ja 1,1 µg/ml kassidel saavutati vastavalt ligikaudu 2,5 tundi ja 1,5 tundi pärast manustamist.
English: In case of accidental self-injection, seek medical advice immediately and show this package insert or
Estonian: Juhuslikul ravimi süstimisel iseendale pöörduge viivitamatult arsti poole ja näidake pakendi infolehte
English: If side effects occur, treatment should be discontinued.
Estonian: Kõrvaltoimete tekkimisel tuleb ravi katkestada.
English: Elimination:
Estonian: Eritumine:
English: Pack sizes: Single 10 ml injection vial.
Estonian: Pakendi suurused: Üks 10 ml viaal süstelahusega.
English: Colourless type I glass injection vial of 10 ml, closed with a grey EPDM rubber stopper and sealed with a flip-off aluminium violet seal.
Estonian: Värvitu klaasist 10 ml süsteviaal, suletud kummikorgiga ja tihendatud alumiiniumkaanega.
English: Dogs:
Estonian: Kassidel:
English: Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.
Estonian: Koertel: Põletiku ja valu leevendamine ägedate või krooniliste lihas-skeleti kahjustuste korral.
English: Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery: single subcutaneous injection before surgery, for example at the time of induction of anaesthesia.
Estonian: Operatsioonijärgse valu vähendamine pärast ovariohüsterektoomiat või väiksemat pehmete kudede operatsiooni: ühekordne subkutaanne süste enne operatsiooni, näiteks anesteesiaravimi manustamise
English: C. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT
Estonian: C. MÜÜGILOA TINGIMUSED VÕI PIIRANGUD OHUTU JA EFEKTIIVSE
English: The safety of the veterinary medicinal product has not been established during pregnancy and
Estonian: Veterinaarravimi ohutus tiinuse ja laktatsiooni perioodil ei ole piisavalt tõestatud.
English: A. MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH
Estonian: A. TOOTMISLOA HOIDJA, KES VASTUTAB RAVIMIPARTII VÄLJASTAMISE EEST
English: Special precautions to be taken by the person administering the veterinary medicinal product to
Estonian: Antud veterinaarravimit loomadele manustava isiku poolt rakendatavad spetsiaalsed
English: B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION
Estonian: B. MÜÜGILOA TINGIMUSED VÕI PIIRANGUD TARNIMISE VÕI KASUTAMISE
English: Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy have occasionally been reported.
Estonian: Aeg-ajalt on teatatud tüüpilistest mittesteroidsete põletikuvastaste ravimite kõrvaltoimetest, nt isutus, oksendamine, kõhulahtisus, peiteveri roojas, apaatia ja neerupuudulikkus.
English: DK-7171 Uldum Denmark
Estonian: North Harrow, Middlesex HA1 4HF
English: MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR
Estonian: Partii väljastamise eest vastutav tootja
English: OTHER INFORMATION
Estonian: ERIHOIATUSED
English: Dogs: single administration of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg).
Estonian: Koertele: ühekordne annus 0,2 mg meloksikaami 1 kg kehamassi kohta (s.t 0,4 ml/10 kg).
English: The volume of distribution is 0.3 l/kg in dogs and 0.09 l/kg in cats.
Estonian: Jaotusruumala on koertel 0,3 l/kg ja
English: For post-operative pain relief in cats, safety has only been documented after thiopental/halothane
Estonian: Operatsioonijärgseks valuvaigistamiseks kassidel on ohutus tõestatud ainult pärast
English: 4.4 Special warnings for each target species
Estonian: 4.4 Erihoiatused
English: Do not use after the expiry date stated on the carton and the vial after EXP. Shelf-life after first opening the container: 28 days.
Estonian: Pärast pakendil ja viaalil märgitud kõlblikkusaja lõppu pärast EXP mitte kasutada.
English: Special precautions for use in animals
Estonian: SOOVITUSED ÕIGE MANUSTAMISVIISI OSAS
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Estonian: MIINIMUMNÕUDED ANDMETE OSAS, MIS PEAVAD OLEMA ÄRA MÄRGITUD
English: EXPIRY DATE
Estonian: FARMATSEUTILISED ANDMED
English: The European Commission granted a marketing authorisation valid throughout the European Union for Glybera on 25 October 2012.
Estonian: Euroopa Komisjon andis Glybera müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 25. oktoobril
English: What measures are being taken to ensure the safe and effective use of Glybera?
Estonian: Mis meetmed võetakse, et tagada Glybera ohutu ja efektiivne kasutamine?
English: Glybera alipogene tiparvovec
Estonian: Glybera alipogeentiparvovek
English: A risk management plan has been developed to ensure that Glybera is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Glybera võimalikult ohutu kasutamine.
English: For three days before Glybera treatment and for twelve weeks after, patients are given immunosuppressive treatment to reduce the reaction of the body's immune system against the medicine.
Estonian: 3 ööpäeva enne Glybera manustamist ja 12 nädalat selle järel saavad patsiendid immunosupressioonravi, et vähendada organismi immuunsüsteemi reaktsiooni ravimile.
English: The medicine will only be supplied to doctors who have received the appropriate educational materials and will only be used to treat patients participating in the registry.
Estonian: Ravimit tarnitakse üksnes arstidele, kes on saanud vastava teabematerjali, ja seda kasutatakse üksnes patsientidel, kes osalevad ravitulemuste jälgimise registris.
English: The amount of the medicine to inject and the number of injections depend on the patient's weight.
Estonian: Ravimi süstitav kogus ja süstete arv sõltuvad patsiendi kehakaalust.
English: Other information about Glybera
Estonian: Muu teave Glybera kohta
English: The CHMP therefore recommended that the medicine be granted marketing authorisation.
Estonian: Inimravimite komitee soovitas seepärast anda ravimi müügiloa.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Glybera can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Glybera kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Other common side effects reported include headache, tiredness, hyperthermia (high body temperature), contusion (bruising) and increased levels of the enzyme creatine kinase in the blood (a measure of damage to muscle tissue).
Estonian: Teised teatatud sagedad kõrvalnähud on näiteks peavalu, väsimus, hüpertermia (kõrge kehatemperatuur), verevalumid ja ensüümi kreatiinkinaasi suur sisaldus veres (lihaskoe kahjustuse näitaja).
English: In addition, the company has put in place a restricted access programme to ensure that Glybera is used appropriately when the diagnosis is confirmed.
Estonian: Lisaks on ettevõte kehtestanud piiratud ravimikasutuse programmi, et tagada Glybera nõuetekohane kasutamine pärast haiguse diagnoosi kinnitamist.
English: The main measures of effectiveness were the reduction in blood fat levels after meals and the reduction in the number of pancreatitis attacks.
Estonian: Efektiivsuse põhinäitajad olid söömisjärgse rasvasisalduse vähenemine veres ja pankreatiidiepisoodide arvu vähenemine.
English: The full EPAR for Glybera can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Glybera kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: There was also a reduction in the number of pancreatitis attacks in some patients, as well as fewer hospital admissions and stays in intensive care units.
Estonian: Samuti vähenes mõnel patsiendil pankreatiidiepisoodide arv ja haiglaravi vajadus ning intensiivraviosakonnas viibimise aeg oli lühem.
English: The majority of patients who received Glybera also received immunosuppressive treatment.
Estonian: Enamik Glyberat manustavatest patsientidest said ka immunosupressioonravi.
English: Anticoagulant medicines, which can increase bleeding, must not be used from the week before Glybera treatment to one day after.
Estonian: Verejooksuriski suurendavaid antikoagulante (hüübimisvastaseid ravimeid) ei tohi kasutada nädal enne ja üks ööpäev pärast Glybera manustamist.
English: Glybera must not be used in patients with immunodeficiency (weakened immunity), increased risk of bleeding and muscle disease.
Estonian: Glyberat ei tohi kasutada immuunpuudulikkusega (nõrgenenud immuunsusega) patsiendid ega verejooksude ja lihasehaiguste suure riskiga patsiendid.
English: This is a summary of the European public assessment report (EPAR) for Glybera.
Estonian: See on ravimi Glybera Euroopa avaliku hindamisaruande kokkuvõte.
English: Patients must also not use oral contraceptives.
Estonian: Samuti ei tohi patsiendid samal ajal kasutada suukaudseid kontratseptiive (rasestumisvastaseid vahendeid).
English: What information is still awaited for Glybera?
Estonian: Mis teavet Glybera kohta veel oodatakse?
English: Given the small number of patients treated, these side effects do not provide a complete picture of the frequency and nature of the side effects of Glybera.
Estonian: Uuringus osalenud patsientide väikese arvu tõttu ei anna need andmed täielikku ülevaadet Glybera kõrvalnähtude esinemissagedusest ja iseloomust.
English: Due to the multiple injections required, it is advisable to give it with a spinal or regional anaesthetic (medicines which numb certain parts of the body to block pain).
Estonian: Et süsteid on vaja mitu, on Glyberat soovitatav manustada spinaal- või regionaalanesteesias (anesteesiameetod, mis muudab organismi teatud piirkonna valu suhtes tundetuks).
English: The modified viral material used in Glybera does not cause infections and cannot make copies of itself.
Estonian: Glyberas kasutatav modifitseeritud viirusmaterjal ei põhjusta infektsioone ja see ei paljune nagu viirus.
English: For more information about treatment with Glybera, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Glyberaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Although there were data for only a small number of patients, the results indicate that Glybera would be of benefit to those patients with severe or multiple pancreatitis attacks.
Estonian: Kuigi andmed pärinevad vähestelt patsientidelt, näitavad uuringutulemused, et Glybera võib olla raskete või korduvate pankreatiidiepisoodidega patsientidele kasulik.
English: After careful consideration of all the evidence and the circumstances of the disease, including its extreme rarity, the CHMP concluded that the results from studies showed that the benefits of Glybera outweigh its risks in patients with severe or multiple pancreatitis attacks despite following a low-fat diet.
Estonian: Pärast kõigi olemasolevate andmete ja haiguse asjaolude, sealhulgas haiguse väga väikese esinemissageduse hoolikat kaalumist järeldas inimravimite komitee, et uuringutulemuste alusel ületab Glybera kasulikkus raskete või korduvate pankreatiidiepisoodidega patsientidel (kellel need esinevad vaatamata väikese rasvasisaldusega dieedile) ravimiga kaasnevaid riske.
English: The company will also provide patients and healthcare professionals with educational materials, including information on how to administer Glybera and how to manage risks with the medicine.
Estonian: Samuti varustab ettevõte patsiendid ja tervishoiutöötajad teabematerjaliga, mis sisaldab Glybera manustamise ja ravimiga kaasnevate riskide ohjamise teavet.
English: One patient was diagnosed with pulmonary embolism (clots in blood vessels supplying the lungs) seven weeks after treatment.
Estonian: Ühel patsiendil diagnoositi 7 nädalat pärast ravi kopsuemboolia (trombid kopsuarterites).
English: Glybera has been authorised under ‘exceptional circumstances' as it has not been possible to obtain complete information about the medicine, because of the rarity of the disease.
Estonian: Glybera müügiluba anti erandkorras, sest kuna haigus esineb harva, ei olnud võimalik saada Glybera kohta täielikku teavet.
English: Patients with this disease need to be on a strict low-fat diet and are prone to recurring attacks of pancreatitis, which is a severe and life-threatening complication.
Estonian: Selle haigusega patsiendid peavad olema rangel väikese rasvasisaldusega dieedil ning neil võivad raske ja eluohtliku tüsistusena esineda korduvad pankreatiidiepisoodid.
English: Because the number of patients with lipoprotein lipase deficiency is low, the disease is considered ‘rare', and Glybera was designated an ‘orphan medicine' (a medicine used in rare diseases) on 8 March 2004.
Estonian: Et lipoproteiinlipaasi vaegusega patsiente on vähe ja see haigus esineb harva, nimetati Glybera 8. märtsil 2004 harvikravimiks.
English: Glybera has been studied in 27 patients with lipoprotein lipase deficiency on a low-fat diet.
Estonian: Glyberat uuriti 27 lipoproteiinlipaasi vaegusega patsiendil, kes olid väikese rasvasisaldusega dieedil.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Glybera.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: What is the risk associated with Glybera?
Estonian: Mis riskid Glyberaga kaasnevad?
English: What is Glybera?
Estonian: Mis on Glybera?
English: When injected into the muscles, it corrects the lipoprotein lipase deficiency by enabling the muscle cells to produce the enzyme.
Estonian: Lihasesse süstimisel korrigeerib see lipoproteiinlipaasi vaeguse, võimaldades lihasrakkudel seda ensüümi toota.
English: For the full list of all side effects reported with Glybera, see the package leaflet.
Estonian: Glybera kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Under the terms of the authorisation, the company is required to provide further data on fat levels in the blood after meals and on the immune response to Glybera in new patients.
Estonian: Müügiloa tingimuste kohaselt peab ettevõte esitama uute patsientide andmed vere söömisjärgse rasvasisalduse ja Glybera suhtes tekkiva immuunvastuse kohta.
English: Glybera is a medicine that contains the active substance alipogene tiparvovec.
Estonian: Glybera on ravim, mis sisaldab toimeainena alipogeentiparvovekit.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Glybera, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Glybera omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Why has Glybera been approved?
Estonian: Miks Glybera heaks kiideti?
English: Glybera is only for patients whose disease has been confirmed by appropriate genetic testing and who have detectable levels of the lipoprotein lipase enzyme in their blood.
Estonian: Glybera on ette nähtud üksnes nende patsientide raviks, kelle haigus on kinnitatud geenitestiga ja kelle veres on tuvastatavas koguses ensüümi lipoproteiinlipaasi.
English: The most common side effect reported with Glybera was pain in the legs following the injections, which occurred in a third of patients.
Estonian: Glybera kõige sagedam kõrvalnäht, mida esines kolmandikul patsientidest, oli süstimisjärgne valu jalgades.
English: The enzyme produced by these cells can then help to break down fats in the blood, reducing the number of pancreatitis attacks and the severity of the disease.
Estonian: Lihasrakkudes tekkinud ensüüm aitab veres sisalduvaid rasvu lagundada, mis vähendab pankreatiidiepisoodide arvu ja raskust.
English: The data showed a reduction in blood fat levels after meals in some patients.
Estonian: Mõnel patsiendil täheldati söömisjärgse rasvasisalduse vähenemist veres.
English: Glybera is used to treat adults with lipoprotein lipase deficiency who have severe or multiple attacks of pancreatitis (inflammation of the pancreas) despite maintaining a low-fat diet.
Estonian: Glyberat kasutatakse ensüüm lipoproteiinlipaasi vaegusega täiskasvanute raviks, kellel on väikese rasvasisaldusega dieedile vaatamata esinenud rasked või korduvad pankreatiidi (kõhunäärmepõletiku) episoodid.
English: The active substance in Glybera, alipogene tiparvovec, is derived from a virus that has been modified so it can carry the lipoprotein lipase gene into the body's cells.
Estonian: Glybera toimeaine alipogeentiparvovek saadakse viirusest, mida on modifitseeritud viima organismi rakkudesse lipoproteiinlipaasi tekitavat geeni.
English: Glybera should only be prescribed and given under the supervision of a doctor with expertise in treating lipoprotein lipase deficiency and in gene therapy.
Estonian: Glyberat tohib määrata ja manustada ainult lipoproteiinlipaasi vaeguse ravis ning geeniteraapias kogenud arsti järelevalve all.
English: The company will also provide data from a registry to monitor the outcome of patients treated with Glybera, and will add a step to the manufacturing of the product to improve the safety profile.
Estonian: Ettevõte esitab ka Glybera ravitulemuste patsiendiregistri andmed ja lisab ravimi tootmisprotsessi etapi, mis parandab ravimi ohutusprofiili.
English: Glybera is given as a single treatment involving multiple injections into the muscles of the upper and lower legs.
Estonian: Glyberat manustatakse ühe ravikuurina, mis koosneb mitmest süstist reie ja sääre lihastesse.
English: How does Glybera work?
Estonian: Kuidas Glybera toimib?
English: What benefit has Glybera shown during the studies?
Estonian: Milles seisneb uuringute põhjal Glybera kasulikkus?
English: Lipoprotein lipase deficiency is a rare disease in which patients have a defect in the gene for lipoprotein lipase, an enzyme responsible for breaking down fats.
Estonian: Lipoproteiinlipaasi vaegus (LPLD) on harva esinev haigus, mille korral on rasvu lagundavat ensüümi lipoproteiinlipaasi tekitav geen defektne.
English: Glybera is a type of advanced therapy medicine called a ‘gene therapy product'.
Estonian: Glybera on geeniteraapiaravimite hulka kuuluv uudne ravim.
English: How has Glybera been studied?
Estonian: Kuidas Glyberat uuriti?
English: How is Glybera used?
Estonian: Kuidas Glyberat kasutatakse?
English: What is Glybera used for?
Estonian: Milleks Glyberat kasutatakse?
English: For more information on the dose of Glybera to be given, see the summary of product characteristics (also part of the EPAR).
Estonian: Glybera annuse üksikasjalik teave on ravimi omaduste kokkuvõttes, mis on samuti Euroopa avaliku hindamisaruande osa.
English: This is a subgroup of severely affected patients with a high unmet medical need.
Estonian: Haigus halvendab oluliselt selle patsiendirühma elukvaliteeti ja muud raviviisid puuduvad.
English: Blister (unit-dose)
Estonian: Blister (üheannuseline)
English: Unit-dose blister
Estonian: Üheannuseline blister 60×1 tabletti
English: • QTc interval 500 msec.
Estonian: • QTc intervall  500 msec.
English: This should be repeated at suitable intervals.
Estonian: Seda tuleb sobivate ajavahemike järel korrata.
English: • Heart rate <45 bpm.
Estonian: • Südame löögisagedus < 45 bpm.
English: o Where at the 6-hour time point:
Estonian: o Kui 6. tunnil on:
English: Continuous (real time) ECG monitoring is recommended.
Estonian: Soovitatav on pidev (reaalajas) EKG jälgimine.
English: o With third degree AV block occurring at any time.
Estonian: o Kolmanda astme AV blokaad ükskõik mis ajahetkel.
English: Concomitant treatment with immunosuppressant or immune-modulating medicines should be avoided.
Estonian: Samaaegset ravi koos immunosupressandi või immunomoduleerivate ravimitega tuleb vältida.
English: • Information about the Fingolimod Pregnancy Exposure Registry
Estonian: • informatsioon fingolimoodi rasedusaegse kasutamise registri kohta;
English: o GILENYA may increase the risk of infections.
Estonian: o GILENYA võib suurendada infektsioonide tekkeriski.
English: • New onset second degree or higher AV block.
Estonian: • Esmaselt tekkinud teise või kõrgema astme AV blokaad.
English: The physician's checklist shall contain the following key messages:
Estonian: Arstidele mõeldud kontroll-leht peab sisaldama järgmisi võtmesõnumeid:
English: o That GILENYA is not recommended in patients with: o Second degree Mobitz Type II or higher AV block o Sick-sinus syndrome o Sino-atrial heart block o QTc prolongation >470 msec (females) or >450 msec (males) o Ischaemic cardiac disease including angina pectoris o Cerebrovascular disease o History of myocardial infarction o Congestive heart failure o History of cardiac arrest o Severe sleep apnoea o History of symptomatic bradycardia o History of recurrent syncope o Uncontrolled hypertension
Estonian: o GILENYA ei ole soovitatav patsientidele, kellel on: o Teise astme Mobitz II tüüpi või kõrgem AV blokaad o Haige siinuse sündroom o Sinuatriaalne südameblokaad o QTc pikenemine > 470 msec (naised) või > 450 msec (mehed) o Isheemiline südamehaigus, sealhulgas stenokardia o Tserebrovaskulaarne haigus o Anamneesis müokardiinfarkt o Kongestiivne südamehaigus o Anamneesis südameseiskumine o Raske uneapnoe o Anamneesis sümptomaatiline bradükardia o Anamneesis korduv sünkoop o Ravimata hüpertensioon
English: Extend heart rate monitoring for at least overnight in a medical facility and until resolution of findings in patients: o Requiring pharmacological intervention during monitoring at treatment initiation.
Estonian: Südame löögisageduse pikendatud jälgimine tervishoiuasutuses vähemalt üle öö ja kuni lahenduseni järgmiste seisundite puhul: o Nõuavad farmakoloogilist sekkumist ravi alustamisega seotud jälgimise jooksul.
English: o Perform an ECG at the end of the 6-hour monitoring period.
Estonian: o 6-tunnise jälgimisperioodi lõpus tuleb teha EKG.
English: o The need to provide patients with the patient reminder card.
Estonian: o Patsientidele tuleb anda patsiendi meeldetuletuskaart.
English: The patient reminder card shall contain the following key messages:
Estonian: Patsiendi meeldetuletuskaart peab sisaldama järgmisi võtmesõnumeid.